A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck
| Autor: | M M Salter, Burkhard Weppelmann, Suzanne Stephens, Sharon A. Spencer, Robert Y. Kim, Ruby F. Meredith, Ricarard H. Wheeler, Glenn E. Peters |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Urology Drug Administration Schedule medicine Humans Radiology Nuclear Medicine and imaging In patient Infusions Intravenous Head and neck Aged Radiation business.industry Head and neck cancer Radiotherapy Dosage Middle Aged medicine.disease Combined Modality Therapy Phase i study Clinical trial Radiation therapy Oncology Carcinoma Basal Cell Head and Neck Neoplasms Fluorouracil Anesthesia Concomitant Carcinoma Squamous Cell Drug Evaluation Female business medicine.drug |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 20:357-360 |
| ISSN: | 0360-3016 |
| Popis: | The radiosensitization properties of 5-FU are well documented, and clinical trials have suggested improved local control and survival in head and neck cancer. Clinical trials to date have used bolus injection or short term (less than or equal to 5 days) 5-FU infusions. To determine the maximum tolerated dose (MTD) of 5-FU given as continuous intravenous infusion for 12 weeks concomitant with conventional radiation therapy, 18 patients with advanced inoperable head and neck cancers were treated with conventional irradiation and 100, 200, 250, or 300 mg/m2/day of 5-FU. A dose of 250 mg/m2/day was determined to be the maximum tolerated dose and is recommended for Phase II studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|